Form 4: Mineralys Therapeutics' Chief Medical Officer Exercises Stock Options
SEC Form 4 Filing
Chief Medical Officer David Malcom Rodman exercised stock options in Mineralys Therapeutics, Inc. on September 11 and 12, 2024.
Summary
- On September 11, 2024, David Malcom Rodman, Chief Medical Officer of Mineralys Therapeutics, exercised stock options to acquire 5,018 shares of common stock at a price of $0.54 per share.
- Following this transaction, Rodman directly owns 119,256 shares of Mineralys Therapeutics common stock.
- On September 12, 2024, Rodman exercised additional stock options to acquire 6,349 shares of common stock at a price of $1.08 per share.
- Following this second transaction, Rodman directly owns 125,605 shares of Mineralys Therapeutics common stock.
- The exercised options were granted previously and vest in monthly installments.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. It doesn't inherently convey positive or negative sentiment about the company's prospects.
Positives
- The exercise of stock options by a company officer can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions and is a standard practice for publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- Shareholders are informed about insider transactions, which can influence their perception of the company's stock.
Key Dates
| Date | Description |
|---|---|
| February 9, 2023 | Date of Reporting Person's Form 3 filing. |
| March 12, 2022 | 25% of the underlying shares of the first stock option vested. |
| July 12, 2023 | 25% of the underlying shares of the second stock option vested. |
| September 11, 2024 | Rodman exercised stock options to acquire 5,018 shares of common stock at $0.54 per share. |
| September 12, 2024 | Rodman exercised stock options to acquire 6,349 shares of common stock at $1.08 per share. |
| September 12, 2024 | Date of the signature on the Form 4 filing. |
| March 11, 2031 | Expiration date of the first stock option. |
| July 11, 2032 | Expiration date of the second stock option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.